---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-023381"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:13:37.945041+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MoonLake's sonelokimab hits HiSCR75 with 29 ppt delta (p=0.0002) in Phase 2 HS trial

## Summary
- Primary endpoint HiSCR75 met with 29 ppt delta vs placebo (p=0.0002) at week 12.
- HiSCR50 achieved 38 ppt delta (p<0.0001), highest delta observed for any molecule in HS.
- Secondary endpoints including HiSCR90, IHS4, and patient-reported pain/quality of life met statistical significance.
- Safety profile consistent with known IL-17 inhibitor class; no new safety signals observed.
- Dose of 120mg performed similarly to 240mg; 120mg considered optimal for further development.

## SEC filing metadata
- accession: 0001628280-23-023381
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/0001628280-23-023381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000162828023023381/mltx-20230626.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-023381
- JSON: https://secwatch.observer/filing/0001628280-23-023381.json
- Plain text: https://secwatch.observer/filing/0001628280-23-023381.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.